Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 341-358

  Piana, Chiara ^a   Antunes, Natalicia De Jesus ^b   Della Pasqua, Oscar ^a,c,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drugs; Epilepsy; Individualized medicine; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; PKPD relationships

Indexed keywords

ANTICONVULSIVE AGENT;

DOSE RESPONSE; EPILEPSY; GENETIC POLYMORPHISM; GENETICS; HUMAN; MUTATION; PHARMACOGENETICS; PROCEDURES; THEORETICAL MODEL;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS; MODELS, THEORETICAL; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84894161525     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.872630     Document Type: Review

References (127)

1. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 2006;10:57-65
2. Sirven JI, Noe K, Hoerth M, Drazkowski J. Antiepileptic drugs 2012: Recent advances and trends. Mayo Clin Proc 2012;87:879-89 . The authors focus on the prediction of serious adverse events in ethnic populations.
3. Cavalleri GL, McCormack M, Alhusaini S, et al. Pharmacogenomics and epilepsy: The road ahead. Pharmacogenomics 2011;12:1429-47. This article provides an overview of study designs that are required to speed up the identification of clinically relevant genetic factors.
4. Reid CA, Jackson GD, Berkovic SF, Petrou S. New therapeutic opportunities in epilepsy: A genetic perspective. Pharmacol Ther 2010;128:274-80
5. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-9
6. Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: A pharmacogenomic update. Expert Opin Parmacother 2007;8:1441-9
7. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-60
8. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-62
9. Sills GJ. Pharmacogenetics of epilepsy: One step forward? Epilepsy Curr 2005;5:236-8
10. Pandolfo M. Genetics of epilepsy. Semin Neurol 2011;31:506-18
11. Patsalos PN. Antiepileptic drug pharmacogenetics. Ther Drug Monit 2000;22:127-30
12. Mann MW, Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: A review. CNS Drugs 2007;21:143-64
13. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1-23. Understanding of the genetic influences on epilepsy outcome and new therapeutic strategies for individuals with epilepsy.
14. Tan NCK, Berkovic SF. The Epilepsy Genetic Association Database (epiGAD): Analysis of 165 genetic association studies, 1996-2008. Epilepsia 2010;51:686-9
15. Lopez M, Dorado P, Monroy N, et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. Drug Metabol Drug Interact 2011;26:5-12
16. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007;46:271-9
17. Dlugos DJ, Buono RJ, Ferraro TN. Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. Pharmacogenomics J 2006;6:357-9
18. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63(10 Suppl 4):S3-8
19. Sporis D, Bozina N, Basic S, et al. Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Coll Antropol 2013;37(1):41-5
20. Spear BB. Pharmacogenetics and antiepileptic drugs. Epilepsia 2001;42:31-4
21. Ferraro TN. Role of genetics in the diagnosis and treatment of epilepsy. Pharmacogenomics 2012;13:731-4
22. Depondt C. Epilepsy pharmacogenetics: Science or fiction? Med Sci 2013;29:189-93
23. Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia 2013;54:33-40
24. Piana C, Surh L, Furst-Recktenwald S, et al. Integration of pharmacogenetics and pharmacogenomics in drug development: Implications for regulatory and medical decision making in pediatric diseases. J Clin Pharmacol 2012;52:704-16
25. Glauser TA. Advancing the medical management of Epilepsy: Disease modification and pharmacogenetics. J Child Neurol 2002;17(1 Suppl):S85-93 . Selection of antiepileptic drugs and dosage regimens based on a patient's clinical characteristics and genotype.
26. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol 2004;3:729-35. This review looks at the evidence that guides the decision of which AED to start as monotherapy and aims to aid the choice of treatment if monotherapy fails.
27. Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 2005;61:25-34 . This is the first report on the haplotype structures of EPHX1 and their potential effects in vivo.
28. Makmor-Bakry M, Sills GJ, Hitiris N, et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin Neuropharmacol 2009;32:205-12
29. Kim W-J, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 2010;20:249-56
30. Simon C, Stieger B, Kullak-Ublick GA, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007;115:232-42
31. Chung W-H, Hung S-I, Wang H-S, et al. A marker for Stevens- Johnson syndrome. Nature 2004;428:1
32. Cheung YK, Cheng SH, Chan EJ, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013;54:1307-14
33. Hung S-I, Chung W-H, Jee S-H, et al. Genetic susceptibility to carbamazepineinduced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306
34. Man CBL, Kwan P, Baum L, et al. Association between HLA-B 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-18
35. Wang Q, Zhou J, Zhou L, et al. Association between HLA-B 1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011;20:446-8
36. Chen P, Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLA-B 1502 screening in Taiwan. N Engl J Med 2011;364:1126-33
37. Zhang Y, Wang J, Zhao L, Peng W. Strong association between HLA-B 1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011;67(9):885-7
38. Wu XT, Hu FY, An DM, et al. Association between carbamazepineinduced cutaneous adverse drug reactions and the HLA-B 1502 allele among patients in central China. Epilepsy Behav 2010;19:405-8
39. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLAB 1502 allele in Thai population. Epilepsia 2008;49:2087-91
40. Tassaneeyakul W, Jantararoungtong T, Pavakul K, et al. Association between HLA-B 1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010;51:926-30 . An overview is presented of the positive predictive value (PPV) and negative predictive value (NPV) of the HLA-B 1502.
41. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, et al. HLA-B 1502 strongly predicts stevens - johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic. Pain Pract 2012;12:202-8 . The screening for this marker is used to assess the risk of this serious side effects.
42. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: Ethnicity matters. Pharmacogenomics J 2006;6:265-8
43. Kaniwa N, Saito Y, Aihara M, et al. HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461-5
44. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A 3101 and Carbamazepine- Induced Hypersensitivity Reactions in Europeans. N Engl J Med 2011;364:1134-43
45. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-18
46. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: Ethnicity matters. Pharmacogenomics J 2006;6:265-8
47. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010;51:297-300
48. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A - 3101 allele as a genetic risk factor for carbamazepine- induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034-41
49. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005;102:5507-12
50. Zhou B-T, Zhou Q-H, Yin J-Y, et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 2012;18:566-72
51. Ebid A-HIM, Ahmed MMM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: A gene polymorphism perspective study.Ther Drug Monitoring. 2007;29:305-12
52. Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol 2008;66:304-7
53. Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006;7:551-61
54. Zhou B-T, Zhou Q-H, Yin J-Y, et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 2012;39:379-84
55. Manna I, Gambardella A, Bianchi A, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 2011;52:e40-4
56. Kumari R, Lakhan R, Kumar S, et al. SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 2013;95:1350-3
57. Grover S, Bala K, Sharma S, et al. Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie 2010;92:1207-12
58. Haerian BS, Lim KS, Mohamed EH, et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 2011;20:387-94
59. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999;40(Suppl 6):S39-50; discussion S73-4
60. Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008;83:416-21
61. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007;113:165-83
62. Gulcebi MI, Ozkaynakci A, Goren MZ, et al. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 2011;95:1-8
63. Blanca Sanchez M, Herranz JL, Leno C, et al. UGT2B7-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 2010;32:177-84
64. Lovric M, Božina N, Hajnšek S, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit 2012;34:518-25
65. Sterjev Z, Trencevska GK, Cvetkovska E, et al. The association of C3435T singlenucleotide polymorphism, Pgpglycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychol Dis Treat 2012;8:191-6
66. Hung S, Chung W, Liu Z, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens - Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-56 . Drugs causing SJS/TEN in HLA-B 1502 carriers may also contribute to the pathomechanism of the disease.
67. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-83
68. Abou-Khalil B. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf 2005;28:871-90
69. Helmstaedter C, Mihov Y, Toliat MR, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 2013;54:36-44
70. Shorvon S. Oxcarbazepine: A review. Seizure 2000;9:75-9
71. Kazeem GR, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009;19:661-5
72. Chen Y-C, Chu C-Y, Hsiao C-H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B 1502 genotype. J Eur Acad Dermatol Venereol 2009;23:702-3
73. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: A critical review. Epilepsia 2004;45:1141-9
74. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. J Clin Pharm Ther 2006;31(3):275-82
75. Goto S, Seo T, Murata T, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007;29:118-21
76. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69
77. Aynacioglua S, Brockmöller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999;48:409-15
78. Ninomiya H, Mamiya K, Matsuo S, et al. Polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000;22:230-2
79. Allabi AC, Gala J, Horsmans Y. Genetic polymorphisms of CYP2C9 and phenytoin metabolism in a Black Beninese population. Br J Clin Pharmacol 2003;56:653-7
80. Chaudhry AS, Urban TJ, Lamba JK, et al. CYP2C9 1B promoter polymorphisms, in linkage with CYP2C192, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther 2010;332:599-611
81. Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A. Severe phenytoin toxicity in a CYP2C9 3 3 homozygous mutant from India. Neurol India 2007;55:408-9
82. McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care 2009;10:222-4 . This case reveals the clinical significance of genetic polymorphisms and its effects on phenytoin dosage requirements.
83. Rosemary J, Surendiran A, Rajan S, et al. Influence of the CYP2C9 & CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 2006;123:665-70
84. Kerb R, Aynacioglua S, Brockmöller J, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-10
85. Tate SK, Singh R, Hung C-C, et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006;16:721-6
86. Hu F, Wu X, An D, et al. Pilot association study of oxcarbazepineinduced mild cutaneous adverse reactions with HLA-B 1502 allele in Chinese Han population. Seizure 2011;20:160-2
87. Twardowschy CA, Werneck LC, Scola RH, et al. The role of CYP2C9 polymorphisms in phenytoinrelated cerebellar atrophy. Seizure 2013;22:194-7
88. Phabphal K, Geater A, Limapichart K, et al. Role of CYP2C9 polymorphism in phenytoin-related metabolic abnormalities and subclinical atherosclerosis in young adult epileptic patients. Seizure 2013;22:103-8
89. Thakkar AN, Bendkhale SR, Taur SR, et al. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurol India 2012;60:577-80
90. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol 2007;40:448-52
91. Murali M, Manjari T, Madhuri B, et al. Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. CNS Neurosci Ther 2012;18:350-8
92. Dorado P, Lopez-Torres E, Penas-Lledo EM, et al. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J 2013;13:359-61
93. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988;15:367-89
94. Chu X-M, Zhang L-F, Wang G-J, et al. Influence of UDP- glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 2012;68:1395-401
95. Tan L, Yu J-T, Sun Y-P, et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010;112:320-3
96. Fukushima Y, Seo T, Hashimoto N, et al. Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum gammaglutamyltransferase in valproic acidtreated patients. Clin Chim Acta 2008;389:98-102
97. Saruwatari J, Deguchi M, Yoshimori Y, et al. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res 2012;99:183-6
98. Stewart JD, Horvath R, Baruffini E, et al. Polymerase g gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (Baltimore, MD) 2010;52:1791-6
99. Okada Y, Seo T, Ishitsu T, Wanibuchi A. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Ther Drug Monit 2008;30:540-3
100. Surh LC, Pacanowski MA, Haga SB, et al. Learning from product labels and label changes: How to build pharmacogenomics into drugdevelopment programs. Pharmacogenomics 2010;11(12):1637-47
101. Bellanti F, Kagedal B, Della Pasqua O. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? Eur J Clin Pharmacol 2011;67(Suppl 1):87-107
102. Sallas WM, Milosavljev S, D'souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003;74:138-49 . Evaluation of drug-drug interactions of oxcarbazepine with coadministered antiepileptic drugs in children.
103. Correa T, Rodriguez I, Romano S. Population Pharmacokinetics of Valproate in Mexican Children with Epilepsy. Biopharm Drug Dispos 2008;520:511-20 . Covariate effects on body weight and daily dose of valproate and concomitant therapy.
104. Falcao A, Fuseau E, Nunes T. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures. CNS Drugs 2012;26:79-91
105. Park K-J, Kim J-R, Joo EY, et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol 2012;35:40-4
106. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol 2007;64:14-26 . This article shows the use of a modelbased approach to assess the power of in vivo studies needed to discern the effect of genotype on pharmacokinetics (PK) and pharmacodynamics (PD) using CYP2C9 and (S)-warfarin as an example.
107. Piana C, Castro FA, Lanchote VL, et al. Optimal sampling and model-based dosing algorithm for busulfan in bone marrow transplantation patients. PAGE 2013.22: Abstract 2776. Available from: Www.page-meeting.org/?abstract=2776
108. Abbasi N, Vadnais B, Knutson JA, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol 2011;51:1429-38
109. Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics 2009;10:1729-32
110. Krivoy N, Zuckerman T, Elkin H, et al. Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: Prediction of poor drug metabolism to prevent drug toxicity. Curr Drug Saf 2012;7:211-17
111. Clinckers R, Smolders I, Michotte Y, et al. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. Br J Pharmacol 2008;155:1127-38
112. Makmor-Bakry M, Sills GJ, Hitiris N, et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin Neuropharmacol 2009;32:205-12
113. Meng H, Guo G, Ren J, et al. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 2011;21:27-30
114. Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B. Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 2013;69:1285-91
115. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008;17:524-30
116. Ponnala S, Chaudhari JR, Jaleel MA, et al. Role of MDR1 C3435T and GABRG2 C588T gene polymorphisms in seizure occurrence and MDR1 effect on anti-epileptic drug (phenytoin) absorption. Genet Test Mol Biomarkers 2012;16:550-7
117. Guo Y, Hu C, He X, et al. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokin 2012;27:536-42
118. Ho PC, Abbott FS, Zanger UM, Chang TKH. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003;3:335-42
119. Ueda K, Ishitsu T, Seo T, et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 2007;8:435-42
120. Phabphal K, Geater A, Limapichart K, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia 2013;54:249-55
121. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010;66:689-96
122. Azzato EM, Chen RA, Wacholder S, et al. Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenet Genomics 2010;20:58-63
123. Costa E, Vieira E, Dos Santos R. The polymorphism c.-3279T>G in the phenobarbital responsive enhancer module of the bilirubin UDPglucuronosyltransferase gene is associated with Gilbert syndrome. Clin Chem 2005;51:2202-4 . Relevance of the screening for the presence of alterations in the phenobarbital-responsive enhancer sequence of the UGT1A1 gene.
124. Grover S, Talwar P, Gourie-devi M, et al. Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics 2010;11:1525-34
125. Depondt C, Godard P, Espel RS, et al. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011;18:1159-64
126. Krekels EH, van den Anker JN, Baiardi P, et al. Pharmacogenetics and paediatric drug development: Issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 2007;8:1787-99. General guidelines on how to incorporate PGt findings into label statements.
127. Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: A regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011;10:495-506